Liquid biopsy diagnostics for tumor monitoring and early recurrence detection
武汉康测科技 develops minimal residual disease (MRD) detection products using liquid biopsy gene sequencing. The tech stack—Python, R, Go, C/C++, Snakemake—reflects a research-driven, genomics-focused engineering approach. A striking hiring imbalance (118 sales roles vs. 8 engineers across ~9 employees) signals a company prioritizing market expansion over product development, consistent with their pain-point focus on market penetration, hospital channel access, and cost reduction rather than platform innovation.
Notable leadership hires: Sales Director
武汉康测科技 is a diagnostics company based in Wuhan specializing in liquid biopsy technology for oncology. Their core product line centers on MRD (minimal residual disease) detection and early tumor recurrence identification, marketed under product names including kc-smp and kc-irquant. Active projects focus on commercializing gene detection technology, expanding into early recurrence detection markets, and promoting tumor gene testing products to hospital networks. The company operates across China and maintains hiring activity in the Netherlands.
Primary languages are Python, R, Go, and C/C++, with Snakemake for workflow automation and Linux as the operating system. Frontend stack includes Vue, HTML, and JavaScript. Tools also include Perl and standard office/design software (PowerPoint, Photoshop).
Headquartered in Wuhan, Hubei Province, China. The company is actively recruiting in both China and the Netherlands.
Other companies in the same industry, closest in size